Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies By admin / 10/12/2023
Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data By admin / 10/11/2023
Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies By admin / 10/11/2023
Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II By admin / 06/01/2023
Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytolysis (ADCC) Relative to Other Anti-CD20 mAbs By admin / 04/25/2023
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies By admin / 04/24/2023
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 04/24/2023
Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 02/23/2023
Early, Transient Shift in Hematologic Parameters Observed With Ublituximab in the ULTIMATE I and II Phase 3 Studies By admin / 02/23/2023
